DiaMedica Reports Phase 2 Preeclampsia Results & Q2 2026 Financials
Company announced positive Phase 2 top-line results for DM199 in preeclampsia and completed enrollment for its fetal growth restriction trial, projecting cash runway through 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day